Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- BerGenBio ASA
- Target Recruit Count
- 40
- Registration Number
- NCT02424617
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Moffit Cancer Centre, Tampa, Florida, United States
🇺🇸Mary Crowley Cancer Research Unit, Dallas, Texas, United States
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
- Conditions
- Interventions
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 545
- Registration Number
- NCT02411448
- Locations
- 🇺🇸
UCLA Hematology/Oncology - Santa Monica, Los Angeles, California, United States
🇺🇸AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇯🇵Hyogo Prefectual Amagasaki General Medical Center, Amagashiki, Hyogo, Japan
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
- Conditions
- Interventions
- First Posted Date
- 2015-02-04
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT02355431
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 597
- Registration Number
- NCT02352948
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)
- Conditions
- Interventions
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 8
- Registration Number
- NCT02342353
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
- Conditions
- Interventions
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02318368
- Locations
- 🇦🇺
Frankston Hospital, Frankston, Victoria, Australia
🇮🇹IRCCS Ospedale S.Raffaele, Milano, Italy
🇮🇹IRCCS Istituto Clinico Humanitas, Rozzano MI, Italy
Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations
- Conditions
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Registration Number
- NCT02277457
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
- Conditions
- Interventions
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT02273362
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
- Conditions
- Interventions
- First Posted Date
- 2014-09-15
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 15
- Registration Number
- NCT02239952
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Noord-Holland, Netherlands
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
- Conditions
- Interventions
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 250
- Registration Number
- NCT02233049
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.